SeekingAlpha · Sep 30, 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow
2026-09-30. The following slide deck was published by ProQR Therapeutics N.V.
NASDAQ · PRQR
ProQR Therapeutics N.V.
Healthcare · Biotechnology
$1.64
Up+$0.01 (+0.31%)
Updated Oct 4, 2026, 4:09 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 249.67M
- P/E ratio
- -5.37
- Dividend yield
- 0.00%
- 52-week range
- $1.35 – $2.46
- Volume
- 622.64K
- Avg. volume
- 502.75K
Price performance · PRQR
PRQR price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
PRQR closed at $1.64 after 19 trading sessions, down 20.24% for the selected period.
- Last close
- $1.64
- Period change
- -20.24%
- Period low
- $1.63
- Period high
- $2.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $1.65 | $1.665 | $1.62 | $1.635 | 622.64K |
| Oct 1, 2026 | $1.66 | $1.6861 | $1.55 | $1.63 | 1.97M |
| Sep 30, 2026 | $1.67 | $1.69 | $1.64 | $1.66 | 678.47K |
| Sep 29, 2026 | $1.66 | $1.70 | $1.63 | $1.65 | 382.27K |
| Sep 28, 2026 | $1.69 | $1.69 | $1.62 | $1.65 | 471.63K |
| Sep 25, 2026 | $1.72 | $1.72 | $1.63 | $1.65 | 584.82K |
| Sep 24, 2026 | $1.70 | $1.725 | $1.66 | $1.71 | 604.38K |
| Sep 23, 2026 | $1.89 | $1.89 | $1.69 | $1.70 | 1.14M |
| Sep 22, 2026 | $1.87 | $1.91 | $1.84 | $1.90 | 433.85K |
| Sep 21, 2026 | $1.86 | $1.8799 | $1.815 | $1.86 | 407.26K |
| Sep 18, 2026 | $1.89 | $1.89 | $1.83 | $1.83 | 570.09K |
| Sep 17, 2026 | $1.90 | $1.9199 | $1.87 | $1.89 | 432.95K |
| Sep 16, 2026 | $1.85 | $1.9017 | $1.79 | $1.86 | 741.89K |
| Sep 15, 2026 | $1.89 | $1.89 | $1.79 | $1.84 | 721.67K |
| Sep 14, 2026 | $1.88 | $1.88 | $1.8114 | $1.86 | 630.05K |
| Sep 11, 2026 | $1.97 | $1.98 | $1.85 | $1.86 | 581.23K |
| Sep 10, 2026 | $1.96 | $1.96 | $1.915 | $1.94 | 479.99K |
| Sep 9, 2026 | $2.05 | $2.125 | $1.97 | $1.99 | 958.27K |
| Sep 8, 2026 | $2.07 | $2.11 | $2.02 | $2.05 | 449.2K |
Latest PRQR news
The latest Smart Investors Daily articles mentioning PRQR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PRQR research
Overview
Company profile and research snapshot.
Company profile
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $3.63
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Chardan Capital | Buy | — |
| Oct 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | B of A Securities | Buy | — |
| Jun 29, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Jones Trading | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 30, 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call September 30, 2026 11:00 AM EDTCompany ParticipantsSarah Kiely - Vice President of Investor...
Yahoo · Sep 23, 2026
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipelineAX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development pro
Yahoo · Sep 9, 2026
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. AX-0811 is ProQR’s next-generation, AI-discovered investigational RNA editing oligon
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
